Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is ...

Viridian Therapeutics (VRDN) remains a 'Sell' as both lead TED assets underperform versus Amgen’s Tepezza, with limited ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Event context and recent share performance Viridian Therapeutics (VRDN) has drawn fresh attention after a sharp pullback, with the stock showing a 29% decline over the past week and about a 51% ...

The average one-year price target for Viridian Therapeutics (NasdaqCM:VRDN) has been revised to $36.18 / share. This is a decrease of 11.71% from the prior estimate of $40.98 dated March 25, 2026. The ...

Not content with lining up one potential rival to Amgen’s Tepezza, Viridian Therapeutics has scored a phase 3 win for another thyroid eye disease (TED) prospect. But the candidate's inability to meet ...

Truist lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $40 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 earnings in Biotech.

The data did not meet investor expectations, and could bring “fierce investor debate on commercial feasibility,” according to ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...

According to a filing with the Securities and Exchange Commission dated February 17, 2026, Commodore Capital reported selling its entire 3,200,000-share stake in Viridian Therapeutics. The net ...

Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in ...

Commodore Capital exited 3,200,000 shares of Viridian Therapeutics. As a result, the net position value decreased by $69.06 million due to the complete share sale. The position was previously 3.4% of ...